FDA Withdraws Draft Guidance For Conjugated Estrogen Products
This article was originally published in The Pink Sheet Daily
Technological advances since the 2000 draft guidance allow for the possibility of using different methodologies, FDA says.
You may also be interested in...
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.
Firm believes the drug, SNS-595, could offer an improved toxicity profile over GSK's Hycamtin.